HUMA vs. LLY

Last updated Jun 4, 2026

HUMA (Humacyte, Inc.) and LLY (Eli Lilly and Company) are both stocks. Both are in the Healthcare sector — HUMA in Biotechnology, LLY in Drug Manufacturers - General. Over the past 3 years, HUMA returned -26.67%/yr vs 35.56%/yr for LLY. At a 0.10 correlation, their price movements are largely independent.

Performance

HUMA vs. LLY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Humacyte, Inc. (HUMA) and Eli Lilly and Company (LLY). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, HUMA achieves a 45.76% return, which is significantly higher than LLY's 0.72% return.

HUMA

• 1D: 0.72%
• 1M: 51.38%
• YTD: 45.76%
• 6M: 8.53%
• 1Y: -46.36%
• 3Y*: -26.67%
• 5Y*: —
• 10Y*: —

LLY

• 1D: 1.37%
• 1M: 11.64%
• YTD: 0.72%
• 6M: 4.73%
• 1Y: 44.70%
• 3Y*: 35.56%
• 5Y*: 41.13%
• 10Y*: 32.66%

*Multi-year figures are annualized to reflect compound growth (CAGR)

HUMA vs. LLY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
HUMA Humacyte, Inc.	45.76%	-80.98%	77.82%	34.60%	-70.90%	-33.85%
LLY Eli Lilly and Company	0.72%	40.25%	33.30%	60.91%	34.26%	6.05%

Correlation

The correlation between HUMA and LLY is 0.14, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.14
Correlation (3Y) Calculated over the trailing 3-year period	0.12
Correlation (All Time) Calculated using the full available price history since Aug 27, 2021	0.10

Fundamentals

Market Cap HUMA : $276.99M LLY : $966.48B
EPS HUMA : -$0.58 LLY : $28.14
PS Ratio HUMA : 116.28 LLY : 13.41
PB Ratio HUMA : 23.83 LLY : 30.98
Total Revenue (TTM) HUMA : $2.02M LLY : $72.25B
Gross Profit (TTM) HUMA : -$13.55M LLY : $59.75B
EBITDA (TTM) HUMA : -$173.00M LLY : $32.97B

Return for Risk

HUMA vs. LLY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HUMA

HUMA Risk / Return Rank: 25
HUMA Sharpe Ratio Rank: 23
HUMA Sortino Ratio Rank: 30
HUMA Omega Ratio Rank: 30
HUMA Calmar Ratio Rank: 20
HUMA Martin Ratio Rank: 23

LLY

LLY Risk / Return Rank: 72
LLY Sharpe Ratio Rank: 75
LLY Sortino Ratio Rank: 70
LLY Omega Ratio Rank: 71
LLY Calmar Ratio Rank: 73
LLY Martin Ratio Rank: 74

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

HUMA vs. LLY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Humacyte, Inc. (HUMA) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	HUMA	LLY	Difference
Sharpe ratio: Return per unit of total volatility	-0.42	1.19	-1.61
Sortino ratio: Return per unit of downside risk	-0.00	1.75	-1.75
Omega ratio: Gain probability vs. loss probability	1.00	1.24	-0.24
Calmar ratio: Return relative to maximum drawdown	-0.59	1.90	-2.49
Martin ratio: Return relative to average drawdown	-0.91	4.73	-5.63
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

HUMA vs. LLY - Sharpe Ratio Comparison

The current HUMA Sharpe Ratio is -0.42, which is lower than the LLY Sharpe Ratio of 1.19. The chart below compares the historical Sharpe Ratios of HUMA and LLY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	HUMA	LLY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.42	1.19	-1.61
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	1.26	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	1.09	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.36	0.57	-0.93

Drawdowns

HUMA vs. LLY - Drawdown Comparison

The maximum HUMA drawdown since its inception was -96.62%, which is greater than LLY's maximum drawdown of -68.24%. Use the drawdown chart below to compare losses from any high point for HUMA and LLY.

Drawdown Indicators

	HUMA	LLY	Difference
Max Drawdown Largest peak-to-trough decline	-96.62%	-68.24%	-28.38%
Max Drawdown (1Y) Largest decline over 1 year	-78.96%	-23.64%	-55.32%
Max Drawdown (3Y) Largest decline over 3 years	-93.93%	-34.48%	-59.45%
Max Drawdown (5Y) Largest decline over 5 years	—	-34.48%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-34.48%	—
Current Drawdown Current decline from peak	-91.76%	-4.26%	-87.50%
Average Drawdown Average peak-to-trough decline	-76.27%	-19.22%	-57.05%
Ulcer Index Depth and duration of drawdowns from previous peaks	51.24%	9.49%	+41.75%

Volatility

HUMA vs. LLY - Volatility Comparison

Humacyte, Inc. (HUMA) has a higher volatility of 39.67% compared to Eli Lilly and Company (LLY) at 9.16%. This indicates that HUMA's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	HUMA	LLY	Difference
Volatility (1M) Calculated over the trailing 1-month period	39.67%	9.16%	+30.51%
Volatility (6M) Calculated over the trailing 6-month period	79.15%	26.81%	+52.34%
Volatility (1Y) Calculated over the trailing 1-year period	110.83%	37.88%	+72.95%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	97.68%	32.79%	+64.89%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	97.68%	30.14%	+67.54%

Dividends

HUMA vs. LLY - Dividend Comparison

HUMA has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.60%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
HUMA Humacyte, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
LLY Eli Lilly and Company	0.60%	0.56%	0.67%	0.78%	1.07%	1.23%	1.75%	1.96%	1.94%	2.46%	2.77%	2.37%

Financials

Frequently Asked Questions

Can I hold both HUMA and LLY in my portfolio?

HUMA and LLY have a correlation of 0.14, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, HUMA or LLY?

HUMA has higher volatility (39.67%) compared to LLY (9.16%). In terms of maximum drawdown, HUMA dropped -96.62% vs LLY's -68.24%.

Which has better risk-adjusted returns?

LLY currently has the higher Sharpe Ratio (1.19 vs -0.42), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.